Abstract
The mobilizing potential and therapeutic activity of ifosfamide/vinorelbine-containing regimens with G-CSF support were explored in patients with pretreated malignant lymphomas. Ten patients with non-Hodgkin's lymphoma (NHL) received ifosfamide and vinorelbine, and 17 with Hodgkin's disease (HD) received ifosfamide, vinorelbine and gemcitabine (IGEV regimen), as induction chemotherapy before high-dose chemotherapy (HDT) with peripheral blood stem cell (PBSC) support. Most of the patients had been heavily pretreated with various chemotherapy regimens ± radiotherapy. The target yield was ⩾3 × 106 CD34+ cells/kg of body weight in order to support the subsequent myeloablative chemotherapy. The optimal PBSC harvest occurred on days 11 and 12, with no difference in CD34+ cell mobilization kinetics between the ifos- famide/vinorelbine and IGEV regimens. The median number of CD34+ cells/kg body weight collected was 10.9 × 106 (range 1.76–61.1 × 106). The median total CD34+ cell/μl, CFU-GM and white blood cells (WBC) for all individual collections was 81.5/μl, 10 × 104/kg, and 17 900/μl, respectively. The target yield of CD34+ cells was reached in 24 of 27 patients. Hematological side-effects were acceptable and no treatment-related hospitalizations or toxic deaths occurred. Fifteen patients have so far received high-dose therapy and PBSC reinfusion with rapid engraftment. These results confirm that ifosfamide and vinorelbine-based chemotherapy regimen with G-CSF support can be successfully and safely used to mobilize PBSCs. Bone Marrow Transplantation (2001) 28, 923–927.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial Lancet 1993 341: 1051–1054
Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540–1545
Schmitz N, Linch DC, Dreger P et al. Randomized trial of filgrastim peripheral progenitor cell transplantation vs autologous bone marrow transplantation in lymphoma patients Lancet 1996 347: 353–357
To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants Bone Marrow Transplant 1992 9: 277–284
Shipp MA, Abeloff MD, Antman G et al. International consensus conference on high-dose therapy with hemopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: report of the jury J Clin Oncol 1999 17: 423–429
Desikan KR, Jagannath S, Vesole D et al. Collection of peripheral blood stem cell mobilisation (PBSC) in multiple myeloma following G-CSF with or without high-dose cyclophosphamide Blood 1995 86 (Suppl. 1): 1594
Janssen WE, Hiemenz J, Zorsky J et al. Mobilisation of peripheral blood stem cells: comparing cell collections from cyclophosphamide and growth factor based regimens Exp Hematol 1993 21: 567
Vahdat L, Raptis G, Fennelly D et al. Superiority of high-dose cyclophosphamide + G-CSF versus either lower dose cyclophosphamide + G-CSF or G-CSF alone in mobilisation of peripheral blood progenitor cells (PBSCs) Blood 1993 82 (Suppl. 1): 2558
Zeller W, Gutensohn K, Stockschlader M et al. Increase of mobilised CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of testis Bone Marrow Transplant 1996 17: 709–713
Cesana C, Regazzi E, Garau D et al. Clonogenic potential and phenotypic analysis of CD34+ cells mobilised by different chemotherapy regimens Haematologica 1999 84: 771–778
Cesana C, Carlo-Stella C, Regazzi E et al. CD34+ cells mobilised by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilised by G-CSF Bone Marrow Transplant 1998 21: 561–568
Benchekroun S, Chouffai Z, Harif M et al. Clinical study of Navelbina activity in Hodgkin's disease. Phase II study. In: Fabre P (ed.) Navelbine (Vinorelbine): Update and New Trends J Libbey: Paris 1991 pp 261–264
Eghabali H . Phase II study of vinorelbine (Navelbine) in previously treated Hodgkin's disease and non-Hodgkin's lymphoma. In: Fabre P (ed.) Navelbine (Vinorelbine): Update and New Trends J Libbey: Paris 1991 pp 253–260
Devizzi L, Santoro A, Bonfante V et al. Vinorelbine: an active drug in the management of patients with heavily pre-treated Hodgkin's disease Ann Oncol 1994 5: 817–820
Devizzi L, Santoro A, Bonfante V et al. Vinorelbine: a new promising drug in Hodgkin's disease Leuk Lymphoma 1995 18: 179–184
Fermè C, Oberlin O, Bouabdallah K et al. Methil-Gag, ifosfamide, navelbine, etoposide (MINE) as salvage therapy for refractory or relapsed Hodgkin's disease (HD) Proc Am Soc Clin Oncol 1991 10: 278a
Fermè C, Bastion Y, Lepage E et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease Ann Oncol 1995 6: 543–549
Bonfante V, Viviani S, Santoro A et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease Br J Haematol 1998 103: 533–553
Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study J Clin Oncol 2000 18: 2615–2625
Balzarotti M, Magagnoli M, Castagna L et al. IGEV chemotherapy and consolidation with peripheral blood stem cell transplantation (PBSCT) for refractory-relapsed Hodgkin's disease (HD) Proc Am Soc Clin Oncol 2001 20: 293a
Ozer H, Armitage JO, Bennet CL et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines J Clin Oncol 2000 18: 3558–3566
Watts MJ, Sullivan AM, Jamieson E et al. Progenitor cell mobilisation after low dose cyclophosphamide and granulocyte colony stimulating factor; an analysis of progenitor cell quantity and quality and factors predicting for these parameters in 101 pre-treated patients with malignant lymphoma J Clin Oncol 1997 15: 535–546
Baars JW, Holtkamp MJ, Nooyen WJ et al. Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (filgrastim) in patients with malignant lymphomas or solid tumors Anticancer Res 1996 16: 3089–3095
McQuacker G, Haynes AP, Stainer C et al. Stem cell mobilisation in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosfamide, etoposide and epirubicin compared to intermediate dose of cyclophosphamide Br J Haematol 1997 98: 228–223
Fermè C, Brice P, Gabarre J et al. MINE chemotherapy plus RhGMCSF as salvage and peripheral blood progenitor cell mobilising regimen for relapsed or refractory Hodgkin's disease Blood 1994 84 (Suppl. 1): 635
Aurlien E, Holte H, Pharo A et al. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma Bone Marrow Transplant 1998 21: 873–878
Petit J, Boquè C, Cancelas JA et al. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single–center study of 22 patients Leuk Lymphoma 1999 34: 119–127
Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma J Clin Oncol 1999 17: 3776–3785
Weaver CH, Schwartzberg L, Li W et al. High-dose chemotherapy and autologous peripheral blood progenitor cell transplants for the treatment of Hodgkin's disease Bone Marrow Transplant 1996 17: 715–731
Jacquy C, Soree A, Lambert F et al. A quantitative study of PBSC contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilise malignant cells Br J Haematol 2000 110: 631–639
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Magagnoli, M., Sarina, B., Balzarotti, M. et al. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant 28, 923–927 (2001). https://doi.org/10.1038/sj.bmt.1703265
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703265
Keywords
This article is cited by
-
Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT
Annals of Hematology (2011)
-
Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma
Bone Marrow Transplantation (2009)
-
IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients
Bone Marrow Transplantation (2007)
-
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
Bone Marrow Transplantation (2006)
-
ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients
Bone Marrow Transplantation (2006)